By Ron Leuty – Staff Reporter, San Francisco Business Times
The company, called 4D Molecular Therapeutics Inc., doesn't expect to put its first three experimental single-shot cures for a range of diseases into clinical trials until next year. Yet it already has key partnerships with well-known drug makers Roche, AstraZeneca plc and gene therapy pioneer uniQure NV. Founders David Schaffer, The Hubbard Howe Jr. Distinguished Professor of Biochemical Engineering, and Dr. David Kirn have worked on so-called "viral vectors" — the protein shells ridden by viruses to skip through the body — since before the company was formed in 2013. In gene therapy, those vehicles are engineered to remove the disease-triggering part of a virus and used instead to carry correct versions of genes to replace mutated genes.
Over the past 150 years, UC Berkeley has been at the forefront of scientific discovery, achieving milestones that have impacted both the research industry and the surrounding community.
Notable figures and facilities across campus have engaged in and continue to engage in progressing the scientific realm of society, whether it be founding modern statistical theory, producing plutonium...
Over the past 150 years, UC Berkeley has been at the forefront of scientific discovery, achieving milestones that have impacted both the research industry and the surrounding community.
The collaborators hope 
Dr. Ramelmeier discusses the future needs of talent in the biomanufacturing industry.